Johnson & Johnson — the strategy behind it

Company profile

Industry: Pharmaceutical Preparations
Listed: NYSE: JNJ
Incorporated: NJ
Headquarters: New Brunswick, NJ
Fiscal year end: Jan 3

Financials

FY2025

Revenue: $94.2B
Net income: $26.8B
Total assets: $199.2B

Johnson & Johnson — reported revenue, net income and total assets by fiscal year, from SEC filings
Fiscal year	Revenue	Net income	Total assets
FY2025	$94.2B	$26.8B	$199.2B
FY2024	$88.8B	$14.1B	$180.1B
FY2023	$85.2B	$35.2B	$167.6B
FY2023	$80.0B	$17.9B	$187.4B
FY2022	$78.7B	$20.9B	$182.0B
FY2021	$82.6B	$14.7B	$174.9B

Reported fiscal years from SEC filings (10-K) — SEC EDGAR ↗. Stratrix is a strategy publication, not a real-time financial data service.

In depth

Strategic Fork

Johnson & Johnson's Tylenol Recall (1982)

When cyanide-laced Tylenol capsules killed seven people in Chicago in 1982, Johnson & Johnson faced an existential threat. CEO James Burke's decision to recall every bottle in America — against the advice of the FBI and FDA — cost $100 million but created the modern playbook for corporate crisis response. Within a year, Tylenol had recaptured nearly all of its market share.

Decisions on record

2 verified Decision Records on Johnson & Johnson, and the casebook each one belongs to.

Fork date	Decision type	The story	Casebook
2021	Adjacency Expansion	Read the story →	Adjacency Expansion Casebook →
2022	The Fork	Read the story →	The Fork Casebook →

Run one of these yourself

The decisions Johnson & Johnson faced, as kits you can run.

Each pack takes one of these decisions and gives you the framework, a deck for the room, a model that resolves to one number, and the sourced cases behind it. $499, one-time.

Crisis & ReinventionThe Crisis ResponseWhat is one more quarter of not acting worth?See the pack →Growth & PortfolioThe Adjacency ExpansionWhen does the business next door belong to you?See the pack →Decision ForksThe Road Not TakenWhat did the decision you did not take actually cost?See the pack →

The analyses

The Crisis Response · Crisis & Reinvention

The $100 Million Recall That Saved a Brand: How J&J Wrote the Playbook for Crisis Response

In 1982, someone laced Tylenol with cyanide and seven people died. Johnson & Johnson could have deflected blame. Instead it pulled 31 million bottles, ate a $100 million loss, and told the public everything. It's still the gold standard - because the most profitable crisis response is the one that ignores profit.

8 min

The Adjacency Expansion · Growth & Portfolio

J&J Spent 130 Years Becoming a Household Name. Then It Spun the Household Out.

J&J started in 1886 making sterile surgical dressings and bought its way into drugs, devices, and the bathroom cabinet. In 2023 it cut the baby powder loose to chase the molecules - the largest restructuring in its 135-year history.

7 min

The Fork · Decision Forks

J&J's $35 Abiomed Bonus Puts Half Its Value on a $3.7B Sales Bar, Not the FDA Win

J&J paid $380 a share for Abiomed and dangled up to $35 more in a non-tradeable CVR. Coverage framed it around clinical milestones, but the filing shows $17.50 of that $35 - exactly half - rides on hitting $3.7 billion in sales, and it halves to $8.75 if the target arrives late.

7 min